PI-RADS v2评分在5α还原酶抑制剂治疗患者中预测前列腺癌的价值
本研究纳入75例接受度他雄胺治疗的患者,行mpMRI及US/MRI融合穿刺活检,评估PI-RADS评分预测前列腺癌的效能并探索PSA及PSA密度阈值。结果显示PI-RADS 4-5的敏感度78.0%、特异度78.7%,PI-RADS 3-4-5敏感度100%、特异度21.3%;总PSA 6 ng/ml和PSA密度>0.22为推荐活检的最佳截断值。
要点
- 度他雄胺治疗患者中PI-RADS 4-5预测前列腺癌敏感度78.0%、特异度78.7%。
- PI-RADS 3-4-5敏感度100%但特异度仅21.3%,阴性预测值100%。
- 总PSA 6 ng/ml和PSA密度>0.22为推荐前列腺活检的最佳阈值。
核心结论
- 在度他雄胺治疗患者中,PI-RADS评分预测前列腺癌具有足够准确性。
主要发现
- PI-RADS 4-5组敏感度78.0%、特异度78.7%、阳性预测值79.6%、阴性预测值77.1%。
- PI-RADS 3-4-5组敏感度100%、特异度21.3%、阳性预测值57.5%、阴性预测值100%。
- PI-RADS 4-5初穿组敏感度71.4%、特异度75.0%、阳性预测值78.9%、阴性预测值66.7%。
- PI-RADS 4-5非初穿组敏感度82.8%、特异度80.6%、阳性预测值80%、阴性预测值83.3%。
- PI-RADS 3-4-5初穿组敏感度100%、特异度31.3%、阳性预测值65.6%、阴性预测值100%。
关键数值与推荐
- ROC曲线分析显示总PSA 6 ng/ml为推荐前列腺活检的最佳截断值(AUC 0.71,95%CI 0.60-0.81)。
- PSA密度>0.22为推荐前列腺活检的最佳截断值(AUC 0.70,95%CI 0.6-0.81)。
临床怎么用
- 对度他雄胺治疗患者可参考PI-RADS评分评估前列腺癌风险。
- 结合总PSA 6 ng/ml和PSA密度>0.22阈值辅助决定是否行前列腺活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate if the PI-RADS score represents an effective tool in detecting prostate cancer in patients treated with a 5α-reductase inhibitor (dutasteride) and to identify dedicated total serum PSA and PSA density thresholds. METHODS: Between April 2015 and March 2018, 75 patients under dutasteride treatment underwent multi-parametric magnetic resonance imaging (mpMRI) scans and US/MRI fusion prostate biopsy. Lesions were classified into two groups: Group 1 included PI-RADS 4 and 5 lesions, whilst Group 2 included PI-RADS 3-4-5 lesions. Lesions in groups 1 and 2 were further divided according to the patients' history of previous prostate biopsy. RESULTS: Ninety-seven lesions were detected. In PI-RADS 4-5 group, mpMRI showed a sensitivity of 78.0% and a specificity of 78.7%. The positive predictive value (PPV) was 79.6% and the negative predictive value (NPV) 77.1%. In PI-RADS 3-4-5 group, sensitivity was 100%, specificity 21.3%, PPV 57.5%, NPV 100%. In PI-RADS 4-5 biopsy-naive group sensitivity was 71.4%, specificity 75.0%. PPV 78.9% and NPV 66.7%. In PI-RADS 4-5 non-biopsy-naive group sensitivity was 82.8%, specificity 80.6%, PPV 80%, and NPV 83.3%. PI-RADS 3-4-5 biopsy-naive group showed sensitivity 100%, specificity 31.3%, PPV 65.6%, NPV 100%. PI-RADS 3-4-5 non-biopsy-naive group showed sensitivity 100%, specificity 16.1%, PPV 52.7%, and NPV 100%. ROC curve analysis indicated a serum total PSA threshold of 6 ng/ml (AUC: 0.71-95% confidence interval: 0.60-0.81) and a PSA density >0.22 (AUC: 0.70-95% confidence interval: 0.6-0.81) as optimal cut-offs for recommending prostate biopsy. CONCLUSIONS: In our experience the PI-RADS score proved to be sufficiently accurate in predicting prostate cancer in patients under dutasteride therapy.
引用
- Forte V, Cavallo AU, Bertolo R, et al. PI-RADS score v.2 in predicting malignancy in patients undergoing 5α-reductase inhibitor therapy. Prostate Cancer Prostatic Dis. 2020. PMID: 32681155. doi:10.1038/s41391-020-0256-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。